Consideration of sex and gender differences in addiction medication response.
Consideration of sex and gender differences in addiction medication response.
复制标题
DOI：
10.1186/s13293-022-00441-3
复制
发表时间：
2022-06-27
影响因子：
7.9
通讯作者：
中科院分区：
文献类型：
--
作者：
在美国，药物使用继续导致女性和男性的重大发病率和死亡率，这一点比其他可预防的健康状况更严重。为了减少可归因于物质的公共健康负担，国家药物滥用研究所和国家酒精滥用和酒精中毒研究所已经确定，开发治疗药物使用障碍的药物是一个高度优先的研究领域。此外，这两个研究所都表示，对药物使用药物开发中的性别和性别差异的研究是一个关键领域。当前叙述性回顾的目的是强调在治疗药物使用障碍的药物试验中如何考虑(或不考虑)性别和性别，澄清和总结关于性别和性别疗效差异的已知内容，并为该领域提供方向，以促进与当前NIH‘性别作为生物变量’(SABV)政策相一致的药物开发。为此，我们审查了主要类别的滥用物质(尼古丁、酒精、可卡因、大麻、阿片类药物)，表明在成瘾药物开发研究中没有很好地考虑性别和性别。然而，当对性别和性别差异的充分数据进行评估时(即戒烟方面)，在女性和男性之间发现了临床上显著的反应差异。在审查的其他滥用药物中，数据还表明，性别和性别可能会预测某些药物的结果，尽管临床研究样本中女性的比例相对较低，限制了得出明确结论。我们建议将性别和性别纳入临床护理指南，并改进从药物开发调查中获得公开的性别分层数据的机会。在美国，药物使用继续导致严重的发病率和死亡率。为了减少可归因于物质的公共健康负担，国家药物滥用研究所和国家酒精滥用和酒精中毒研究所已经确定，开发治疗药物使用障碍的药物是一个高度优先的研究领域。我们回顾了滥用物质的主要类别(尼古丁、酒精、可卡因、大麻、阿片类药物)，表明在成瘾药物开发研究中，性别和性别没有得到很好的考虑。当对性别和性别差异的充分数据进行评估时(即戒烟方面)，在女性和男性之间发现了临床上显著的反应差异。然而，这些数据在临床护理指南中根本没有考虑到。我们建议更好地获取药物开发调查中公开的性别分层数据，以便为临床实践提供信息，并改善向患有药物使用障碍的妇女提供的治疗。
Substance use continues to contribute to significant morbidity and mortality in the United States, for both women and men, more so than another other preventable health condition. To reduce the public health burden attributable to substances, the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism have identified that medication development for substance use disorder is a high priority research area. Furthermore, both Institutes have stated that research on sex and gender differences in substance use medication development is a critical area. The purpose of the current narrative review is to highlight how sex and gender have been considered (or not) in medication trials for substance use disorders to clarify and summarize what is known regarding sex and gender differences in efficacy and to provide direction to the field to advance medication development that is consistent with current NIH ‘sex as a biological variable’ (SABV) policy. To that end, we reviewed major classes of abused substances (nicotine, alcohol, cocaine, cannabis, opioids) demonstrating that, sex and gender have not been well-considered in addiction medication development research. However, when adequate data on sex and gender differences have been evaluated (i.e., in tobacco cessation), clinically significant differences in response have been identified between women and men. Across the other drugs of abuse reviewed, data also suggest sex and gender may be predictive of outcome for some agents, although the relatively low representation of women in clinical research samples limits making definitive conclusions. We recommend the incorporation of sex and gender into clinical care guidelines and improved access to publicly available sex-stratified data from medication development investigations. Substance use continues to contribute to significant morbidity and mortality in the United States. To reduce the public health burden attributable to substances, the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism have identified that medication development for substance use disorder is a high priority research area. We reviewed major classes of abused substances (nicotine, alcohol, cocaine, cannabis, opioids) demonstrating that, sex and gender have not been well-considered in addiction medication development research. When adequate data on sex and gender differences have been evaluated (i.e., in tobacco cessation), clinically significant differences in response have been identified between women and men. However, these data are not at all considered in clinical care guidelines. We recommend improved access to publicly available sex-stratified data from medication development investigations, to inform clinical practice and to improve treatment provided to women with substance use disorders.
登录
查看更多内容
影响因子：
4.2
作者：
Becker, Jill B.;McClellan, Michele L.;Reed, Beth Glover
通讯作者：
Reed, Beth Glover
影响因子：
3.4
作者：
Herman, Aryeh I;Waters, Andrew J;McKee, Sherry A;Sofuoglu, Mehmet
通讯作者：
Sofuoglu, Mehmet
来自全国代表性样本的孕妇在2002年至2016年之间使用酒精，香烟和大麻。
影响因子：
26.1
作者：
Agrawal A;Rogers CE;Lessov-Schlaggar CN;Carter EB;Lenze SN;Grucza RA
通讯作者：
Grucza RA
影响因子：
2.9
作者：
Anton, Raymond F.;Kranzler, Henry;Han, Jian
通讯作者：
Han, Jian
影响因子：
3.2
作者：
Bold, Krysten W.;Zweben, Allen;O'Malley, Stephanie S.
通讯作者：
O'Malley, Stephanie S.